Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Common Equity (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Common Equity data on record, last reported at $333.3 million in Q1 2026.

  • On a quarterly basis, Common Equity rose 45.87% to $333.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $333.3 million, a 45.87% increase, with the full-year FY2025 number at $349.0 million, up 43.6% from a year prior.
  • Common Equity reached $333.3 million in Q1 2026 per FULC's latest filing, down from $349.0 million in the prior quarter.
  • Over the last five years, Common Equity for FULC hit a ceiling of $349.0 million in Q4 2025 and a floor of $160.8 million in Q2 2022.
  • A 5-year average of $243.8 million and a median of $235.2 million in 2023 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: surged 71.33% in 2023, then dropped 27.9% in 2024.
  • Tracing FULC's Common Equity over 5 years: stood at $198.9 million in 2022, then grew by 18.22% to $235.2 million in 2023, then increased by 3.33% to $243.0 million in 2024, then soared by 43.6% to $349.0 million in 2025, then dropped by 4.5% to $333.3 million in 2026.
  • Business Quant data shows Common Equity for FULC at $333.3 million in Q1 2026, $349.0 million in Q4 2025, and $198.4 million in Q3 2025.